Serum Transthyretin as a Prognostic and Therapeutic Biomarker in Transthyretin Amyloid Cardiomyopathy Patients Treated with Tafamidis.

J Clin Med · 2026 · PMC13164462 · PMID 42123087

Europe PMC DOI

hedged sentence

0.4100

closest p · 8.2× alpha

0.4100

boldest claim

The sentences

did not reach statistical significancep = 0.41not close (p > 0.1)

sTTR levels at 12 and 24 months showed a further slight increase compared with 6 months (37.54 ± 5.8 mg/dL and 38.0 ± 4.9 mg/dL, respectively), which did not reach statistical significance ( p = 0.41 and p = 0.39 vs. 6 months, respectively) ( Figure 1 ).

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.